Copyright
©The Author(s) 2020.
World J Gastroenterol. Dec 28, 2020; 26(48): 7652-7663
Published online Dec 28, 2020. doi: 10.3748/wjg.v26.i48.7652
Published online Dec 28, 2020. doi: 10.3748/wjg.v26.i48.7652
Figure 1 Inclusion of individuals in study analyses.
FIT: Fecal immunohistochemical test; CRC: Colorectal cancer; AN: Advanced neoplasia.
Figure 2 Colonoscopy findings after fecal immunohistochemical test positive result.
Figure 3 Relative risk of diagnosis for symptomatic patients vs eligible patients with 95%CI.
LRA: Low-risk adenoma; HRA: High-risk adenoma; AA: Advanced adenoma; AN: Advanced neoplasia.
Figure 4 Relative risk of diagnosis for fecal immunohistochemical test eligible indigenous vs fecal immunohistochemical test eligible non-indigenous.
LRA: Low-risk adenoma; HRA: High-risk adenoma; AA: Advanced adenoma; AN: Advanced neoplasia.
- Citation: Smith HA, Scarffe AD, Brunet N, Champion C, Kandola K, Tessier A, Boushey R, Kuziemsky C. Impact of colorectal cancer screening participation in remote northern Canada: A retrospective cohort study. World J Gastroenterol 2020; 26(48): 7652-7663
- URL: https://www.wjgnet.com/1007-9327/full/v26/i48/7652.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i48.7652